News NewsletterFeatured ArticlesNewsletter SubscribeEventsMedia Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1 2 December 2015 The presentation can be viewed here (in Swedish)CategoriesNewsPress ReleasesLatest postsAroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder 27 November 2018AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays 27 November 2018AroCells valberedning har haft sitt första möte 20 November 2018Delårsrapport 1 januari – 30 september 2018 14 November 2018Arocell utser Michael Brobjer till ny VD 23 October 2018Archive2018AroCell presenterar resultat från U-CAN TK1 lymfomstudien samt från en studie där TK 210™ ELISA jämförs med andra metoder27 November 2018AroCell presents results from the U-CAN TK1 lymphoma study and from a comparison study between TK 210™ ELISA and other assays27 November 2018AroCells valberedning har haft sitt första möte20 November 2018Delårsrapport 1 januari – 30 september 201814 November 2018Arocell utser Michael Brobjer till ny VD23 October 2018AroCell AB announces the appointment of a new CEO23 October 2018Patent godkänt på den amerikanska marknaden17 October 2018Patent granted in the US17 October 2018Ytterligare ett abstract som visar värdet av AroCells provberedningssteg i samband med diagnostik har accepterats av ISOBM inför mötet i Hamburg 9 October 2018A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method 9 October 2018TK 210 ELISA jämfört med andra metoder18 September 2018TK 210 ELISA compared to other methods18 September 2018Delårsrapport 1 januari – 30 juni 201831 August 2018Anders Hultman ny CFO för AroCell30 August 2018Patent förstärker AroCells möjligheter på den amerikanska marknaden29 August 2018Patent reinforces AroCell’s opportunities in the US market29 August 2018New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker24 August 2018AroCell rekryterar ny CFO10 July 20182018-06-15 Kommuniké från årsstämma15 June 2018Arocell rekryterar ny VD22 May 2018Sista dag för handel med BTA den 22 maj 201817 May 2018Kallelse till årsstämma i Arocell AB (publ)15 May 2018AroCell: Företrädesemissionen i AroCell övertecknad 3 May 2018AroCell offentliggör ett andra tilläggsprospekt27 April 2018Delårsrapport1 januari – 31 mars 201827 April 2018AroCell tecknar licensavtal med Roche – kommentarer från AroCell’s vd25 April 2018AroCell announces license agreement with Roche24 April 2018AroCell tecknar globalt licensavtal med Roche24 April 2018AroCell offentliggör tilläggsprospekt17 April 2018AroCell offentliggör pågående förhandling om utlicensiering och samarbete med stort diagnostikbolag, upprättar tilläggsprospekt och förlänger teckningstiden 6 April 2018Idag inleds teckningstiden i AroCell ABs (publ) företrädesemission om cirka 35 MSEK26 March 2018AroCell offentliggör prospekt, teaser och anmälningssedel20 March 2018AroCell beslutar om en företrädesemission om cirka 35 MSEK (säkerställd/garanterad till 75 %) i syfte att tillföra kapital för klinisk validering, kommersialisering samt licensiering och partnerskap12 March 2018Nya resultat med TK 210™ ELISA kommer att presenteras på AACR 2018, 14 – 19 April i Chicago. 8 March 2018AroCell TK 210 ELISA presented at LabRoots Drug Discovery Virtual Congress February 21-22, 2018 1 March 2018AroCell Delårsrapport 1 oktober – 31 december 201722 February 2018Länk till ProHearings I Stockholm20 February 2018AroCell på ProHearings I Stockholm13 February 2018AroCells valberedning har haft sitt första möte 9 February 2018AroCell på rätt väg!23 January 2018AroCell på den asiatiska marknaden18 January 2018Blodprov förbättrar cellbehandlingen18 January 20182017Julhälsning22 December 2017AroCell AB (publ) signs Letter of Intent with Korean-based company, Green Cross Cell Corporation.22 November 2017AroCell AB (publ) Interim Report, Q3 201722 November 2017Webinar recording is now available20 November 2017Abstract published presenting AroCell TK 210 ELISA from the PROMIX study at the European Society for Medical Oncology Congress in Singapore, November 17-19, 2017 8 November 2017AroCell poster presentations at 2017 NCRI Cancer Conference 1 November 2017AroCell AB: announces that a distribution agreement has been signed with Pathway Diagnostics Ltd, for distribution of the AroCell TK 210 ELISA test in United Kingdom and Ireland.13 October 2017AroCell Research Poster on TK1 / TK 210 ELISA in Prostate Cancer has been accepted for presentation at the UK National Cancer Research Institute (NCRI) Annual Meeting November 201726 September 2017AroCell TK 210 ELISA abstract on in-vitro studies of cancer drugs has been accepted for presentation at the National Cancer Research Institute (NCRI) UK symposium22 September 2017Webinar announcement and invitation20 September 2017New application for AroCell TK 210 ELISA opens new opportunities for drug development research18 September 2017AroCell AB Interim Report, Q2 201724 August 2017TK 210 ELISA appears in latest issue Genetic Engineering & Biotechnology News 7 August 2017Beslut vid årsstämman i AroCell AB (publ) 201718 May 2017AroCell AB (publ) Interim report for period 1 January – 31 March 201711 May 2017AroCell Presentation at 13th Annual Biomarkers & Immuno-Oncology World Congress 2017 in Philadelphia19 April 2017KALLELSE TILL ÅRSSTÄMMA I AROCELL AB (PUBL)13 April 2017AroCell TK 210 ELISA Webinar Recording is now available!28 March 2017AroCell AB (publ) Year-End Report16 February 2017AroCell research poster on prostate cancer has been accepted by American Association for Cancer Research (AARC)24 January 2017Nomination committee appointed for Annual General Meeting 201719 January 20172016Announcement – AroCell AB PR and Marketing Communications Manager19 December 2016Interim report January – September 201617 November 2016Ann Hammarstrand appointed as new CFO to AroCell 3 November 2016AroCell signs distribution agreement with Eagle Biosciences in the United States 6 October 2016New TK 210 ELISA product presentation 2 October 2016Oral presentation today of TK 210 ELISA abstract at ISOBM, Chicago 4 September 2016Interim report January – June 201625 August 2016Improved measurement of Thymidine Kinase 1 within the normal range due to improved composition of the zero calibrator.12 August 2016Nasdaq News Release 1 July 2016AroCell is approved for listing on the Nasdaq First North and publishes Corporate description28 June 2016AroCell applying for listing on the Nasdaq First North exchange21 June 2016Christine Tadgell new board member in AroCell23 May 2016CEO Jan Stålemark’s presentation at the AGM 201619 May 2016Report from the Annual General Meeting of AroCell19 May 2016AroCell Newsletter for May is now available11 May 2016Interim report January – March 201610 May 2016Leading profile in biomarkers joins the AroCell management team 2 May 2016New patent strengthens the AroCell patent portfolio28 April 2016Annual Report 201527 April 2016New clinical study with promising results for the TK 210 ELISA test from AroCell18 April 2016Kallelse till årsstämma i AroCell AB (publ)18 April 2016Final call for trading with BTA 8 January 20162015Nomination committee appointed for Annual General Meeting 201617 December 2015Oversubscription of preferential rights issue 8 December 2015Sign up for our Newsletter! 8 December 2015Presentation by CEO Jan Stålemark at Redeye Investor Forum, December 1 2 December 2015Interview with CEO Jan Stålemark for Analysguiden, November 201530 November 2015Presentation from Stora Aktiedagen Göteborg, November 2330 November 2015AroCell announces prospectus, teaser and application form17 November 2015Progress for development of prostate treatment, results from STHLM3 presented today10 November 2015AroCell announces interim report three will be brought forward 6 November 2015Announcement of fully guaranteed preferential rights issue of approximately 52.2 MSEK 6 November 2015Continued expansion to AroCell organization23 October 2015AroCell presents a robust TK1 blood-test at an international biomarker meeting19 October 2015Clarification regarding press release about CE marking 2 October 2015AroCell announces that it has filed for the CE-mark registration of TK 210 ELISA 1 October 2015AroCell announces achievement of critical milestone: successful phase 1 review of TK 210 ELISA production process.17 August 2015AroCell recognized by EU Commission and Horizon 2020 Program Committee13 August 2015AroCell strengthens the organization 5 June 2015Report from the annual general meeting of AroCell 3 June 2015Notice of annual general meeting of AroCell AB (publ) 6 May 2015Schedule revision providing for CE-mark during third quarter 201512 February 2015Revised schedule means CE-marking during the third quarter of 201512 February 20152014New clinical study with promising results29 October 2014
